Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years

Rationale: Lumacaftor/ivacaftor was approved for the treatment of patients with cystic fibrosis who are homozygous for F508del aged 2 years and older following positive results from phase three trials. However, the improvement in CFTR function associated with lumacaftor/ivacaftor has only been studi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julian Berges (Autor), Simon Y. Graeber (Autor), Susanne Hämmerling (Autor), Yin Yu (Autor), Arne Krümpelmann (Autor), Mirjam Stahl (Autor), Stephanie Hirtz (Autor), Heike Scheuermann (Autor), Marcus A. Mall (Autor), Olaf Sommerburg (Autor)
Formato: Libro
Publicado: Frontiers Media S.A., 2023-05-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible